Immunologic Deficiency Syndromes

11 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Immune System Diseases

Narrower: Primary Immunodeficiency Diseases 4, X-Linked Combined Immunodeficiency Diseases 2

Treatments and conditions

Immunologic Deficiency Syndromes
Treatment and conditionWhere it standsTrials
Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Direct intravenous injection of ivlv-X1 lentiviral vector for x-linked combined immunodeficiency diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Haploidentical Hematopoietic Cell Transplantation for primary immunodeficiency diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paxlovid 10 days for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paxlovid 5 days for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Paxlovid 5 days + REMDESIVIR for immunologic deficiency syndromesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for primary immunodeficiency diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.